QQQ   290.39 (+0.00%)
AAPL   113.85 (-2.97%)
MSFT   210.11 (-0.13%)
FB   268.43 (-0.47%)
GOOGL   1,727.56 (-0.51%)
AMZN   3,098.39 (-0.03%)
TSLA   521.85 (+6.58%)
NVDA   525.60 (+0.40%)
BABA   270.11 (-0.23%)
CGC   24.72 (+4.22%)
GE   10.07 (+3.18%)
MU   64.18 (+4.53%)
AMD   85.31 (+0.79%)
T   28.62 (+1.06%)
NIO   55.38 (+12.45%)
F   8.86 (+1.37%)
ACB   7.18 (+0.70%)
GILD   59.89 (-0.37%)
NFLX   476.62 (-2.38%)
BA   211.53 (+5.97%)
DIS   145.98 (+3.48%)
QQQ   290.39 (+0.00%)
AAPL   113.85 (-2.97%)
MSFT   210.11 (-0.13%)
FB   268.43 (-0.47%)
GOOGL   1,727.56 (-0.51%)
AMZN   3,098.39 (-0.03%)
TSLA   521.85 (+6.58%)
NVDA   525.60 (+0.40%)
BABA   270.11 (-0.23%)
CGC   24.72 (+4.22%)
GE   10.07 (+3.18%)
MU   64.18 (+4.53%)
AMD   85.31 (+0.79%)
T   28.62 (+1.06%)
NIO   55.38 (+12.45%)
F   8.86 (+1.37%)
ACB   7.18 (+0.70%)
GILD   59.89 (-0.37%)
NFLX   476.62 (-2.38%)
BA   211.53 (+5.97%)
DIS   145.98 (+3.48%)
QQQ   290.39 (+0.00%)
AAPL   113.85 (-2.97%)
MSFT   210.11 (-0.13%)
FB   268.43 (-0.47%)
GOOGL   1,727.56 (-0.51%)
AMZN   3,098.39 (-0.03%)
TSLA   521.85 (+6.58%)
NVDA   525.60 (+0.40%)
BABA   270.11 (-0.23%)
CGC   24.72 (+4.22%)
GE   10.07 (+3.18%)
MU   64.18 (+4.53%)
AMD   85.31 (+0.79%)
T   28.62 (+1.06%)
NIO   55.38 (+12.45%)
F   8.86 (+1.37%)
ACB   7.18 (+0.70%)
GILD   59.89 (-0.37%)
NFLX   476.62 (-2.38%)
BA   211.53 (+5.97%)
DIS   145.98 (+3.48%)
QQQ   290.39 (+0.00%)
AAPL   113.85 (-2.97%)
MSFT   210.11 (-0.13%)
FB   268.43 (-0.47%)
GOOGL   1,727.56 (-0.51%)
AMZN   3,098.39 (-0.03%)
TSLA   521.85 (+6.58%)
NVDA   525.60 (+0.40%)
BABA   270.11 (-0.23%)
CGC   24.72 (+4.22%)
GE   10.07 (+3.18%)
MU   64.18 (+4.53%)
AMD   85.31 (+0.79%)
T   28.62 (+1.06%)
NIO   55.38 (+12.45%)
F   8.86 (+1.37%)
ACB   7.18 (+0.70%)
GILD   59.89 (-0.37%)
NFLX   476.62 (-2.38%)
BA   211.53 (+5.97%)
DIS   145.98 (+3.48%)
Log in
NASDAQ:ATNX

Athenex Stock Forecast, Price & News

$14.00
-0.01 (-0.07 %)
(As of 11/23/2020 05:03 PM ET)
Add
Compare
Today's Range
$13.89
Now: $14.00
$14.25
50-Day Range
$11.35
MA: $12.16
$13.96
52-Week Range
$5.63
Now: $14.00
$18.35
Volume711,457 shs
Average Volume667,532 shs
Market Capitalization$1.31 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.88
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and PT01 (Pegtomarginase), an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.
Read More
Athenex logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.83 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATNX
CUSIPN/A
Phone716-427-2950
Employees574

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$101.23 million
Book Value$2.27 per share

Profitability

Net Income$-123,750,000.00

Miscellaneous

Market Cap$1.31 billion
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$14.00
-0.01 (-0.07 %)
(As of 11/23/2020 05:03 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Athenex (NASDAQ:ATNX) Frequently Asked Questions

How has Athenex's stock price been impacted by Coronavirus (COVID-19)?

Athenex's stock was trading at $9.66 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ATNX stock has increased by 44.9% and is now trading at $14.00.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Athenex?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athenex in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Athenex
.

What stocks does MarketBeat like better than Athenex?

Wall Street analysts have given Athenex a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Athenex wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Athenex's next earnings date?

Athenex is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Athenex
.

How were Athenex's earnings last quarter?

Athenex, Inc. (NASDAQ:ATNX) released its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.44) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.46) by $0.02. The company had revenue of $35.48 million for the quarter, compared to the consensus estimate of $19.50 million. Athenex had a negative return on equity of 66.12% and a negative net margin of 75.45%.
View Athenex's earnings history
.

What price target have analysts set for ATNX?

5 analysts have issued twelve-month price objectives for Athenex's shares. Their forecasts range from $22.00 to $33.00. On average, they expect Athenex's stock price to reach $26.60 in the next twelve months. This suggests a possible upside of 90.0% from the stock's current price.
View analysts' price targets for Athenex
.

Are investors shorting Athenex?

Athenex saw a drop in short interest during the month of October. As of October 15th, there was short interest totaling 8,390,000 shares, a drop of 13.8% from the September 30th total of 9,730,000 shares. Based on an average trading volume of 813,600 shares, the days-to-cover ratio is currently 10.3 days. Currently, 11.4% of the company's shares are sold short.
View Athenex's Short Interest
.

Who are some of Athenex's key competitors?

What other stocks do shareholders of Athenex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athenex investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), QUALCOMM (QCOM), Amarin (AMRN), AbbVie (ABBV), Gilead Sciences (gild), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

Who are Athenex's key executives?

Athenex's management team includes the following people:
  • Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D., Chairman & CEO (Age 60, Pay $880.75k)
  • Mr. Randoll Sze, Chief Financial Officer (Age 39, Pay $375.21k)
  • Mr. Jeffrey M. Yordon, COO & Pres of Athenex Pharmaceutical Division (Age 71, Pay $584.76k)
  • Dr. Rudolf Kwan M.D., M.B., B.S., Chief Medical Officer (Age 67, Pay $510.17k)
  • Dr. Simon C. Pedder Ph.D., Chief Bus. & Strategy Officer of Proprietary Products (Age 59, Pay $378.71k)
  • Dr. Allen Barnett, Co-Founder & Pres Emeritus
  • Ms. Teresa Brophy Bair, Gen. Counsel, Sr. VP of Admin. & Corp. Sec.
  • Ms. Jacqueline Li, Director of Corp. Devel. & Investor Relations
  • Mr. Daniel Lang M.D., Sr. Director of Corp. Devel.
  • Mr. John W. Matthei, VP of HR

When did Athenex IPO?

(ATNX) raised $72 million in an IPO on Wednesday, June 14th 2017. The company issued 6,000,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan acted as the underwriters for the IPO and ICBC International was co-manager.

What is Athenex's stock symbol?

Athenex trades on the NASDAQ under the ticker symbol "ATNX."

Who are Athenex's major shareholders?

Athenex's stock is owned by a variety of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (14.50%), BlackRock Inc. (6.37%), State Street Corp (2.99%), Schonfeld Strategic Advisors LLC (0.94%), Assenagon Asset Management S.A. (0.75%) and Deltec Asset Management LLC (0.65%). Company insiders that own Athenex stock include Benson Kwan Hung Tsang, Johnson Yiu Nam Lau, Jordan Kanfer, Life Sciences Maste Perceptive, Manson Fok, Perceptive Advisors Llc, Randoll Sze, Rudolf Kwan, Sheldon Trainor-Degirolamo, Song-Yi Zhang, Stephanie A Davis and William Wei Zuo.
View institutional ownership trends for Athenex
.

Which major investors are selling Athenex stock?

ATNX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, SG Americas Securities LLC, JPMorgan Chase & Co., California Public Employees Retirement System, California State Teachers Retirement System, Morgan Stanley, and New York State Common Retirement Fund.
View insider buying and selling activity for Athenex
.

Which major investors are buying Athenex stock?

ATNX stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Schonfeld Strategic Advisors LLC, Assenagon Asset Management S.A., Deltec Asset Management LLC, Cubist Systematic Strategies LLC, First Trust Advisors LP, ExodusPoint Capital Management LP, and Caas Capital Management LP. Company insiders that have bought Athenex stock in the last two years include Benson Kwan Hung Tsang, Johnson Yiu Nam Lau, Jordan Kanfer, Life Sciences Maste Perceptive, Manson Fok, Perceptive Advisors Llc, Randoll Sze, Rudolf Kwan, Stephanie A Davis, and William Wei Zuo.
View insider buying and selling activity for Athenex
.

How do I buy shares of Athenex?

Shares of ATNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Athenex's stock price today?

One share of ATNX stock can currently be purchased for approximately $14.00.

How big of a company is Athenex?

Athenex has a market capitalization of $1.31 billion and generates $101.23 million in revenue each year. The company earns $-123,750,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. Athenex employs 574 workers across the globe.

What is Athenex's official website?

The official website for Athenex is www.athenex.com.

How can I contact Athenex?

Athenex's mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The company can be reached via phone at 716-427-2950.

This page was last updated on 11/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.